Search research articles
Contact Us
Filters
Showing results (11-20 of 37) with videos related to
Page
of 4
Sort By:
Antimicrobial Agents and Chemotherapy
|
March 6, 2019
Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis
Jian Xu, Si-Yang Li, Deepak V Almeida, et al.
Science (New York, N.Y.)
|
January 6, 2004
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2
Lyubomir T Vassilev, Binh T Vu, Bradford Graves, et al.
Antimicrobial Agents and Chemotherapy
|
December 9, 2024
Contribution of telacebec to novel drug regimens in a murine tuberculosis model
Oliver D Komm, Sandeep Tyagi, Andrew Garcia, et al.
Biorxiv : the Preprint Server for Biology
|
August 23, 2023
The heme oxygenase-1 metalloporphyrin inhibitor stannsoporfin enhances the bactericidal activity of a novel regimen for multidrug-resistant tuberculosis in a murine model
Jennie Ruelas Castillo, Pranita Neupane, Styliani Karanika, et al.
Antimicrobial Agents and Chemotherapy
|
December 22, 2023
The heme oxygenase-1 metalloporphyrin inhibitor stannsoporfin enhances the bactericidal activity of a novel regimen for multidrug-resistant tuberculosis in a murine model
Jennie Ruelas Castillo, Pranita Neupane, Styliani Karanika, et al.
Antimicrobial Agents and Chemotherapy
|
February 20, 2024
Bactericidal and sterilizing activity of novel regimens combining bedaquiline or TBAJ-587 with GSK2556286 and TBA-7371 in a mouse model of tuberculosis
Si-Yang Li, Sandeep Tyagi, Heena Soni, et al.
Cancer Research
|
February 27, 2009
Characterization of a novel mitogen-activated protein kinase kinase 1/2 inhibitor with a unique mechanism of action for cancer therapy
Sherif Daouti, Huisheng Wang, Wen-hui Li, et al.
Molecular Cancer Therapeutics
|
January 8, 2010
Preclinical in vivo evaluation of efficacy, pharmacokinetics, and pharmacodynamics of a novel MEK1/2 kinase inhibitor RO5068760 in multiple tumor models
Sherif Daouti, Brian Higgins, Kenneth Kolinsky, et al.
Mbio
|
April 5, 2023
A Novel Tool to Identify Bactericidal Compounds against Vulnerable Targets in Drug-Tolerant M. tuberculosis found in Caseum
Jansy P Sarathy, Min Xie, Richard M Jones, et al.
Microbiology Spectrum
|
September 15, 2022
The Novel Oxazolidinone TBI-223 Is Effective in Three Preclinical Mouse Models of Methicillin-Resistant Staphylococcus aureus Infection
Oren Gordon, Dustin A Dikeman, Roger V Ortines, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 37) with videos related to
Sort By:
Page
of 4
Antimicrobial Agents and Chemotherapy
|
March 6, 2019
Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis
Jian Xu, Si-Yang Li, Deepak V Almeida, et al.
Science (New York, N.Y.)
|
January 6, 2004
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2
Lyubomir T Vassilev, Binh T Vu, Bradford Graves, et al.
Antimicrobial Agents and Chemotherapy
|
December 9, 2024
Contribution of telacebec to novel drug regimens in a murine tuberculosis model
Oliver D Komm, Sandeep Tyagi, Andrew Garcia, et al.
Biorxiv : the Preprint Server for Biology
|
August 23, 2023
The heme oxygenase-1 metalloporphyrin inhibitor stannsoporfin enhances the bactericidal activity of a novel regimen for multidrug-resistant tuberculosis in a murine model
Jennie Ruelas Castillo, Pranita Neupane, Styliani Karanika, et al.
Antimicrobial Agents and Chemotherapy
|
December 22, 2023
The heme oxygenase-1 metalloporphyrin inhibitor stannsoporfin enhances the bactericidal activity of a novel regimen for multidrug-resistant tuberculosis in a murine model
Jennie Ruelas Castillo, Pranita Neupane, Styliani Karanika, et al.
Antimicrobial Agents and Chemotherapy
|
February 20, 2024
Bactericidal and sterilizing activity of novel regimens combining bedaquiline or TBAJ-587 with GSK2556286 and TBA-7371 in a mouse model of tuberculosis
Si-Yang Li, Sandeep Tyagi, Heena Soni, et al.
Cancer Research
|
February 27, 2009
Characterization of a novel mitogen-activated protein kinase kinase 1/2 inhibitor with a unique mechanism of action for cancer therapy
Sherif Daouti, Huisheng Wang, Wen-hui Li, et al.
Molecular Cancer Therapeutics
|
January 8, 2010
Preclinical in vivo evaluation of efficacy, pharmacokinetics, and pharmacodynamics of a novel MEK1/2 kinase inhibitor RO5068760 in multiple tumor models
Sherif Daouti, Brian Higgins, Kenneth Kolinsky, et al.
Mbio
|
April 5, 2023
A Novel Tool to Identify Bactericidal Compounds against Vulnerable Targets in Drug-Tolerant M. tuberculosis found in Caseum
Jansy P Sarathy, Min Xie, Richard M Jones, et al.
Microbiology Spectrum
|
September 15, 2022
The Novel Oxazolidinone TBI-223 Is Effective in Three Preclinical Mouse Models of Methicillin-Resistant Staphylococcus aureus Infection
Oren Gordon, Dustin A Dikeman, Roger V Ortines, et al.
Page
of 4